clinical effect observation of barley green intervention in hyperuricemia population and related mechanism study of xanthine oxidase

Conditions: Hyperuricemia

Summary: this study aims to explore the changes in metabolic-related indicators in patients with hyperuricemia under the intervention of barley green, reveal the clinical effect of barley green in regulating uric acid metabolism, and preliminarily clarify the mechanism of barley green influencing uric acid metabolism through in vitro experiments related to xanthine oxidase. this study plans to recruit patients with hyperuricemia who visit the clinical nutrition department and rheumatology and immunology department of peking university people's hospital, randomly dividing them into an intervention group and a control group. the intervention group will take barley green plus a balanced diet plan, while the control group will only be given a balanced diet plan. general clinical data will be collected, and nutritional measurements will be conducted. venous blood will be drawn for the determination of uric acid metabolism-related indicators, xanthine oxidase activity, and inflammatory factor levels. the differences in uric acid and related metabolic indicators, as well as xanthine oxidase activity, between the two groups will be observed and compared to provide a scientific basis for the clinical application of barley green in non-pharmacological intervention and medical nutrition therapy for hyperuricemia.


Eligibility criteria:
inclusion criteria: * aged 18 to 65 years old; under a normal purine diet, the fasting blood uric acid level on two different days: 420 μmol/l \< blood uric acid \< 540 μmol/l (for men), 360 μmol/l \< blood uric acid \< 540 μmol/l (for women); willing to accept the assessment and sign the informed consent. exclusion criteria: * ① patients currently receiving drug treatment for hyperuricemia; * patients with diseases affecting food digestion and absorption (such as chronic diarrhea, constipation, severe digestive tract inflammation, active peptic ulcers, post-gastrointestinal resection, cholecystitis/cholecystectomy, etc.); * patients with cardiovascular and cerebrovascular diseases, grade 3 hypertension, chronic hepatitis, malignant tumors, anemia (hemoglobin value below the normal reference range), mental disorders and memory impairment, epilepsy, etc.; * patients simultaneously receiving other functional food nutritional support (plant active substances, health foods); * patients with abnormal liver function (alanine aminotransferase or/and aspartate aminotransferase exceeding 3 times the upper limit of the normal value); patients with abnormal kidney function (serum creatinine exceeding the upper limit of the normal value); * patients with active pulmonary tuberculosis, aids and other infectious diseases; ⑦ patients with severe allergies to the ingredients of the study nutritional product; * pregnant or lactating women; * patients with limb disabilities and those deemed unsuitable for participation in the study by the clinical doctor (for example, patients with severe diseases not listed in the exclusion criteria); ⑩ patients with gouty arthritis attacks ≥ 2 times; ⑪ patients with one gouty arthritis attack and blood uric acid \> 480 μmol/l, or combined with any of the following: age \ 480 μmol/l and combined with any of the following: uric acid nephrolithiasis or renal function impairment (egfr ≤ 89 ml/(min·1.73 m²)), hypertension, impaired glucose tolerance or diabetes, dyslipidemia (any of the four lipid indicators exceeding the normal reference range), obesity (bmi ≥ 28 kg/m²), coronary heart disease, stroke, heart failure.